A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICAC

A5175：第四阶段、前瞻性、随机、开放标签的功效评价

• 批准号: 7604202
• 负责人: ROY M. GULICK
• 金额: $ 0.16万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604202
• 关键词: Anti-Retroviral Agents; CD4 Lymphocyte Count; Cells; Computer Retrieval of Information on Scientific Projects Database; Daily; Evaluation; Funding; Grant; HIV-1; Institution; Label; Persons; Pharmaceutical Preparations; Phase; Protease Inhibitor; RNA-Directed DNA Polymerase; Randomized; Research; Research Personnel; Resources; Source; Treatment Protocols; United States National Institutes of Health; prospective

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypotheses: Three-drug antiretroviral (ARV) regimens administered once-daily and twice-daily provide similar ARV benefit in resource-limited settings for HIV-1- infected persons with CD4+ cell counts <300 cells/mm3. A three-drug ARV regimen containing a protease inhibitor (PI), administered once-daily, provides similar ARV benefit in resource-limited settings for HIV-1-infected persons with CD4+ cell counts <300 cell/mm3 as compared with a three-drug ARV regimen administered twice daily that contains an non-nucleosis reverse transcriptase (NNRTI).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 假设：每天一次给药，每天两次给药的三药抗逆转录病毒（ARV）方案在资源有限的设置中为HIV-1感染的人提供了类似的ARV益处，CD4+细胞计数<300个细胞/MM3。 每天一次施用的含有蛋白酶抑制剂（PI）的三毒ARV方案在资源受限的设置中为HIV-1感染的CD4+细胞计数<300 Cell/Mm3的人提供了类似的ARV益处，与每天使用的三量化twice相比，具有非企业的twice twice cypersise recessermis Repressemis（NNRR）（NNNR）。